CN105873932B - (6S,9aS)‑N‑苄基‑6‑[(4‑羟基苯基)甲基]‑4,7‑二氧‑8‑({6‑[3‑(哌嗪‑1‑基)氮杂环丁烷‑1‑基]吡啶‑2‑基}甲基)‑2‑(丙‑2‑烯‑1‑基)‑八氢‑1H‑吡嗪并[2,1‑c][1,2,4]三嗪‑1‑甲酰胺化合物 - Google Patents
(6S,9aS)‑N‑苄基‑6‑[(4‑羟基苯基)甲基]‑4,7‑二氧‑8‑({6‑[3‑(哌嗪‑1‑基)氮杂环丁烷‑1‑基]吡啶‑2‑基}甲基)‑2‑(丙‑2‑烯‑1‑基)‑八氢‑1H‑吡嗪并[2,1‑c][1,2,4]三嗪‑1‑甲酰胺化合物 Download PDFInfo
- Publication number
- CN105873932B CN105873932B CN201480067017.7A CN201480067017A CN105873932B CN 105873932 B CN105873932 B CN 105873932B CN 201480067017 A CN201480067017 A CN 201480067017A CN 105873932 B CN105873932 B CN 105873932B
- Authority
- CN
- China
- Prior art keywords
- bases
- methyl
- octahydro
- triazine
- pyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC[C@@](C)[C@](CC)CC(C=CC1)=C(C)C=C1[C@]1CC(CCC(CC(C)C(C)(*C)*=C)=C2*CC2)CC1 Chemical compound CC[C@@](C)[C@](CC)CC(C=CC1)=C(C)C=C1[C@]1CC(CCC(CC(C)C(C)(*C)*=C)=C2*CC2)CC1 0.000 description 7
- CRLJCIHYGPHTDI-IBGZPJMESA-N CCN(CC1)[C@@H](C)CN1C(C1)CN1C(c1ccccc1)c1ccccc1 Chemical compound CCN(CC1)[C@@H](C)CN1C(C1)CN1C(c1ccccc1)c1ccccc1 CRLJCIHYGPHTDI-IBGZPJMESA-N 0.000 description 1
- HIQVWLMURZJTMI-KTPUSDJZSA-N CCN(CC1)[C@@H](C)CN1C(C1)CN1c1nc(CN(C[C@@H](C(CC2)[C@H]3Cc(ccc(O)c4)c4F)N(C(NCc4ccccc4)=O)N(CC=C)CC2=O)C3=O)ccc1 Chemical compound CCN(CC1)[C@@H](C)CN1C(C1)CN1c1nc(CN(C[C@@H](C(CC2)[C@H]3Cc(ccc(O)c4)c4F)N(C(NCc4ccccc4)=O)N(CC=C)CC2=O)C3=O)ccc1 HIQVWLMURZJTMI-KTPUSDJZSA-N 0.000 description 1
- UBUGKJPFVFUWMO-BHVANESWSA-N CCOC(CN(Cc1cccc(F)n1)C([C@H](Cc(c(F)cc(OCc1ccccc1)c1)c1F)NC(CN(CC=C)NC(NCc1ccccc1)=O)=O)=O)OCC Chemical compound CCOC(CN(Cc1cccc(F)n1)C([C@H](Cc(c(F)cc(OCc1ccccc1)c1)c1F)NC(CN(CC=C)NC(NCc1ccccc1)=O)=O)=O)OCC UBUGKJPFVFUWMO-BHVANESWSA-N 0.000 description 1
- IIABFQCUZITFET-UHFFFAOYSA-N CN(C)C(CC1)CCN1C1CNC1 Chemical compound CN(C)C(CC1)CCN1C1CNC1 IIABFQCUZITFET-UHFFFAOYSA-N 0.000 description 1
- DZWQQLBLLDVRQM-UHFFFAOYSA-N CN(CCN1CCCCCC1)C(C1)CN1c1cccc(C=O)n1 Chemical compound CN(CCN1CCCCCC1)C(C1)CN1c1cccc(C=O)n1 DZWQQLBLLDVRQM-UHFFFAOYSA-N 0.000 description 1
- KUVDGCAHTKVSLX-CYBMUJFWSA-N C[C@H](C1)N(C)CCN1C(C1)CN1c1nc(C=S(C)C)ccc1F Chemical compound C[C@H](C1)N(C)CCN1C(C1)CN1c1nc(C=S(C)C)ccc1F KUVDGCAHTKVSLX-CYBMUJFWSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013-267687 | 2013-12-25 | ||
| JP2013267687 | 2013-12-25 | ||
| PCT/JP2014/083932 WO2015098853A1 (ja) | 2013-12-25 | 2014-12-22 | （６Ｓ，９ａＳ）－Ｎ－ベンジル－６－［（４－ヒドロキシフェニル）メチル］－４，７－ジオキソ－８－（｛６－［３－（ピペラジン－１－イル）アゼチジン－１－イル］ピリジン－２－イル｝メチル）－２－（プロプ－２－エン－１－イル）－オクタヒドロ－１Ｈ－ピラジノ［２，１－ｃ］［１，２，４］トリアジン－１－カルボキサミド化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105873932A CN105873932A (zh) | 2016-08-17 |
| CN105873932B true CN105873932B (zh) | 2017-11-24 |
Family
ID=53399298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480067017.7A Active CN105873932B (zh) | 2013-12-25 | 2014-12-22 | (6S,9aS)‑N‑苄基‑6‑[(4‑羟基苯基)甲基]‑4,7‑二氧‑8‑({6‑[3‑(哌嗪‑1‑基)氮杂环丁烷‑1‑基]吡啶‑2‑基}甲基)‑2‑(丙‑2‑烯‑1‑基)‑八氢‑1H‑吡嗪并[2,1‑c][1,2,4]三嗪‑1‑甲酰胺化合物 |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US9174998B2 (https=) |
| EP (1) | EP3088401B1 (https=) |
| JP (1) | JP6085040B2 (https=) |
| KR (1) | KR102307053B1 (https=) |
| CN (1) | CN105873932B (https=) |
| AR (1) | AR098908A1 (https=) |
| AU (1) | AU2014371148B2 (https=) |
| BR (1) | BR112016013572B1 (https=) |
| CA (1) | CA2932435C (https=) |
| CL (1) | CL2016001419A1 (https=) |
| CY (1) | CY1122521T1 (https=) |
| DK (1) | DK3088401T3 (https=) |
| ES (1) | ES2728353T3 (https=) |
| HR (1) | HRP20190908T1 (https=) |
| HU (1) | HUE044541T2 (https=) |
| IL (1) | IL245961A0 (https=) |
| JO (1) | JO3809B1 (https=) |
| LT (1) | LT3088401T (https=) |
| ME (1) | ME03391B (https=) |
| MX (1) | MX365376B (https=) |
| MY (1) | MY173946A (https=) |
| PE (1) | PE20160932A1 (https=) |
| PH (1) | PH12016501079A1 (https=) |
| PL (1) | PL3088401T3 (https=) |
| PT (1) | PT3088401T (https=) |
| RS (1) | RS58955B1 (https=) |
| RU (1) | RU2669805C2 (https=) |
| SG (1) | SG11201604496YA (https=) |
| SI (1) | SI3088401T1 (https=) |
| SM (1) | SMT201900306T1 (https=) |
| TR (1) | TR201908392T4 (https=) |
| TW (1) | TWI681961B (https=) |
| UA (1) | UA116923C2 (https=) |
| WO (1) | WO2015098853A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY162940A (en) | 2009-08-19 | 2017-07-31 | Eisai R&D Man Co Ltd | Quinoline derivative-containing pharmaceutical composition |
| JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
| PT3524595T (pt) | 2014-08-28 | 2022-09-19 | Eisai R&D Man Co Ltd | Derivado de quinolina altamente puro e método para produção do mesmo |
| LT3263106T (lt) | 2015-02-25 | 2024-01-10 | Eisai R&D Management Co., Ltd. | Chinolino darinių kartumo sumažinimo būdas |
| KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| MX373231B (es) * | 2015-06-16 | 2020-05-08 | Eisai R&D Man Co Ltd | Agente anticancerigeno. |
| CA2986999C (en) * | 2015-06-23 | 2023-08-08 | Eisai R&D Management Co., Ltd. | Crystal of (6s,9as)-n-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2h-pyrazino[2,1-c][1,2,4]triazine-1(6h)-carboxamide |
| US12220398B2 (en) | 2015-08-20 | 2025-02-11 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
| CN108084067B (zh) * | 2016-11-22 | 2019-08-30 | 重庆圣华曦药业股份有限公司 | 一种立他司特中间体的制备方法 |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| RU2019134940A (ru) | 2017-05-16 | 2021-06-16 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Лечение гепатоцеллюлярной карциномы |
| EP4051278B1 (en) | 2019-10-29 | 2025-12-17 | Eisai R&D Management Co., Ltd. | Combination of a pd-1 antagonist, a vegfr/fgfr/ret tyrosine kinase inhibitor and a cbp/beta-catenin inhibitor for treating cancer |
| US12486275B2 (en) | 2020-03-12 | 2025-12-02 | City Of Hope | Substituted pyrazino[2,1-c][1,2,4]triazines as Wnt/CBP/catenin signaling pathway inhibitors |
| AR121544A1 (es) | 2020-03-12 | 2022-06-15 | 3 2 Pharma | Inhibidores de la vía de señalización por cbp / catenina y sus usos |
| CN117083065A (zh) | 2020-10-30 | 2023-11-17 | 庆应义塾 | 肌肉减少症相关疾病等的新颖治疗和预防 |
| US20240352020A1 (en) * | 2021-08-26 | 2024-10-24 | 3+2 Pharma, Llc | Pyrazole-containing cbp/catenin antagonists and uses thereof |
| MX2024002060A (es) * | 2021-09-08 | 2024-03-01 | Eisai R&D Man Co Ltd | Composicion farmaceutica para tratar tumores solidos. |
| CN116262120A (zh) * | 2021-12-13 | 2023-06-16 | 上海中医药大学 | 特异性结合TRAF2的试剂在制备Wnt通路抑制剂中的应用 |
| WO2023140369A1 (en) * | 2022-01-18 | 2023-07-27 | Prism BioLab Co., Ltd. | Phosphoric acid derivatives |
| EP4473970A4 (en) | 2022-03-31 | 2026-01-21 | Eisai R&D Man Co Ltd | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUMORS |
| CN115784934A (zh) * | 2022-11-22 | 2023-03-14 | 上海吉奉生物科技有限公司 | 一种酪氨酸衍生物的合成方法 |
| AU2023439518A1 (en) | 2023-04-06 | 2025-08-28 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumors |
| WO2025174646A1 (en) * | 2024-02-12 | 2025-08-21 | Albert Einstein College Of Medicine | Inhibitors of beta-catenin c-terminal domain and methods of use |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1585770A (zh) * | 2001-10-12 | 2005-02-23 | 中外药品株式会社 | 回折模拟物及其相关的方法 |
| CN101827849A (zh) * | 2007-10-15 | 2010-09-08 | (株)中外制药 | 新型回折模拟物化合物及其用途(1) |
| CN102046628A (zh) * | 2008-06-06 | 2011-05-04 | 株式会社棱镜生物实验室 | α螺旋拟似物和与其有关的方法 |
| CN103209982A (zh) * | 2010-10-14 | 2013-07-17 | Jw制药公司 | 新颖反转模拟物的化合物、其制造方法及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8080657B2 (en) | 2001-10-12 | 2011-12-20 | Choongwae Pharma Corporation | Compounds of reverse turn mimetics and the use thereof |
| JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
| CA2758904C (en) * | 2009-04-15 | 2017-04-04 | Jw Pharmaceutical Corporation | Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof |
| WO2012115286A1 (en) * | 2011-02-25 | 2012-08-30 | Prism Biolab Corporation | Alpha helix mimetics and methods relating thereto |
-
2014
- 2014-12-19 US US14/577,660 patent/US9174998B2/en active Active
- 2014-12-21 JO JOP/2014/0373A patent/JO3809B1/ar active
- 2014-12-22 WO PCT/JP2014/083932 patent/WO2015098853A1/ja not_active Ceased
- 2014-12-22 PE PE2016000711A patent/PE20160932A1/es unknown
- 2014-12-22 CA CA2932435A patent/CA2932435C/en active Active
- 2014-12-22 PT PT14873998T patent/PT3088401T/pt unknown
- 2014-12-22 SG SG11201604496YA patent/SG11201604496YA/en unknown
- 2014-12-22 TR TR2019/08392T patent/TR201908392T4/tr unknown
- 2014-12-22 SM SM20190306T patent/SMT201900306T1/it unknown
- 2014-12-22 HU HUE14873998 patent/HUE044541T2/hu unknown
- 2014-12-22 KR KR1020167015608A patent/KR102307053B1/ko active Active
- 2014-12-22 BR BR112016013572-5A patent/BR112016013572B1/pt active IP Right Grant
- 2014-12-22 ES ES14873998T patent/ES2728353T3/es active Active
- 2014-12-22 ME MEP-2019-158A patent/ME03391B/me unknown
- 2014-12-22 MX MX2016007705A patent/MX365376B/es active IP Right Grant
- 2014-12-22 RU RU2016122867A patent/RU2669805C2/ru active
- 2014-12-22 EP EP14873998.0A patent/EP3088401B1/en active Active
- 2014-12-22 AR ARP140104850A patent/AR098908A1/es active IP Right Grant
- 2014-12-22 DK DK14873998.0T patent/DK3088401T3/da active
- 2014-12-22 TW TW103144928A patent/TWI681961B/zh active
- 2014-12-22 LT LTEP14873998.0T patent/LT3088401T/lt unknown
- 2014-12-22 AU AU2014371148A patent/AU2014371148B2/en active Active
- 2014-12-22 RS RS20190665A patent/RS58955B1/sr unknown
- 2014-12-22 HR HRP20190908TT patent/HRP20190908T1/hr unknown
- 2014-12-22 CN CN201480067017.7A patent/CN105873932B/zh active Active
- 2014-12-22 PL PL14873998T patent/PL3088401T3/pl unknown
- 2014-12-22 JP JP2015554886A patent/JP6085040B2/ja active Active
- 2014-12-22 UA UAA201606261A patent/UA116923C2/uk unknown
- 2014-12-22 MY MYPI2016702025A patent/MY173946A/en unknown
- 2014-12-22 SI SI201431226T patent/SI3088401T1/sl unknown
-
2016
- 2016-06-01 IL IL245961A patent/IL245961A0/en active IP Right Grant
- 2016-06-07 PH PH12016501079A patent/PH12016501079A1/en unknown
- 2016-06-09 CL CL2016001419A patent/CL2016001419A1/es unknown
-
2019
- 2019-05-31 CY CY20191100578T patent/CY1122521T1/el unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1585770A (zh) * | 2001-10-12 | 2005-02-23 | 中外药品株式会社 | 回折模拟物及其相关的方法 |
| CN101827849A (zh) * | 2007-10-15 | 2010-09-08 | (株)中外制药 | 新型回折模拟物化合物及其用途(1) |
| CN102046628A (zh) * | 2008-06-06 | 2011-05-04 | 株式会社棱镜生物实验室 | α螺旋拟似物和与其有关的方法 |
| CN103209982A (zh) * | 2010-10-14 | 2013-07-17 | Jw制药公司 | 新颖反转模拟物的化合物、其制造方法及其用途 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105873932B (zh) | (6S,9aS)‑N‑苄基‑6‑[(4‑羟基苯基)甲基]‑4,7‑二氧‑8‑({6‑[3‑(哌嗪‑1‑基)氮杂环丁烷‑1‑基]吡啶‑2‑基}甲基)‑2‑(丙‑2‑烯‑1‑基)‑八氢‑1H‑吡嗪并[2,1‑c][1,2,4]三嗪‑1‑甲酰胺化合物 | |
| CN116096710B (zh) | 用于治疗braf相关疾病和障碍的4-氧代-3,4-二氢喹唑啉酮化合物 | |
| CN106795118B (zh) | 杂环化合物和它们作为类视黄醇相关的孤儿受体(ror)gamma-t抑制剂的用途 | |
| CN107614504B (zh) | 甲酰胺化合物的晶体 | |
| EP3919483A1 (en) | Benzopyridone heterocyclic compound and use thereof | |
| NZ713233A (en) | Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease | |
| WO2018181345A1 (ja) | 複素環化合物 | |
| JP2020531423A (ja) | ヒストンメチルトランスフェラーゼ阻害剤としての三環式化合物 | |
| CN105593227A (zh) | 作为端锚聚合酶抑制剂的吡啶并[2,3-d]嘧啶-4-酮化合物 | |
| CN104640859A (zh) | 作为γ分泌酶调节剂的稠合三唑衍生物 | |
| HK1222656B (en) | (6s,9as)-n-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazine-1-yl)azetidine-1-yl]pyridine-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1h-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound | |
| JP2023502279A (ja) | Ｃｐｓ１を阻害するためのピペラジン化合物 | |
| CN114728986A (zh) | 作为mcl-1抑制剂的大环磺酰基衍生物 | |
| WO2016027844A1 (ja) | テトラヒドロイミダゾ［１，５－ｄ］［１，４］オキサゼピン化合物 | |
| NZ720718B2 (en) | (6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]-4,7-DIOXO-8-({6-[3-(PIPERAZINE-1-YL)AZETIDINE-1-YL]PYRIDINE-2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND | |
| NZ713233B2 (en) | (6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]-4,7-DIOXO-8-({6-[3-(PIPERAZINE-1-YL)AZETIDINE-1-YL]PYRIDINE-2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND | |
| HK40009519B (zh) | 具有erk激酶抑制活性的化合物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1222656 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1222656 Country of ref document: HK |